The list that decides which peptides legally exist.

The most consequential document in American peptide policy is not a vote tally from an advisory committee. It is a list in the Code of Federal Regulations, filed at 21 CFR 216.23, and in the twenty-nine years since Congress authorised it, that list has admitted six substances.

Five of the six are restricted to topical use. The sixth is a surgical dye. None of them is a peptide, and none of them is injectable. That is the complete lifetime output of the mechanism that decides which unapproved ingredients a licensed pharmacy may lawfully turn into medicine for an individual patient.

So here is the thesis. The July 2026 advisory vote put nothing on that list, because an advisory committee cannot. Only a final regulation can, and the rulemaking machine that issues those regulations has produced exactly one in twenty-nine years. Everything the peptide economy currently treats as imminent depends on that machine running faster over the next eighteen months than it has run in three decades. I think that is possible. I do not think it is likely, and I think almost nobody selling into this market has priced the difference.

Three doors, and nearly everyone needs the third

Section 503A of the Federal Food, Drug, and Cosmetic Act is the provision that lets a licensed pharmacist compound a drug for an identified patient without that preparation going through the approval process. It is a narrow exemption and it comes with conditions.

The condition that matters here is about the raw material. A bulk drug substance used in 503A compounding has to clear one of three gates. It can comply with an applicable monograph in the United States Pharmacopeia or the National Formulary. It can be a component of a drug the FDA has already approved. Or, if it is neither of those things, it can appear on a list the FDA develops by regulation.

BPC-157, KPV and TB-500 fail the first two gates outright. There is no USP monograph. There is no approved drug containing them. For these molecules the third door is not one option among several. It is the only door in the building, and it opens exactly one way: a final rule, published in the Federal Register, amending the Code of Federal Regulations.

Twenty-nine years, six substances, all of them dermatology or eye surgery

Congress wrote Section 503A into the Act in 1997. Almost nothing happened for the next sixteen years, for reasons that have nothing to do with science. In 2002 the Supreme Court struck down the section's advertising and solicitation restrictions in Thompson v. Western States Medical Center, and the fight over whether the remainder of the section survived left the whole provision effectively dormant.

The Drug Quality and Security Act of 2013, passed after the New England Compounding Center meningitis outbreak, stripped out the unconstitutional language and brought 503A back to life nationwide. The FDA solicited nominations for the bulks list on 4 December 2013 and again on 2 July 2014. The Pharmacy Compounding Advisory Committee, reconstituted under the same law, held its first meeting on 23 and 24 February 2015 and worked through six nominated substances.

The final rule covering that first batch published on 19 February 2019 and took effect on 21 March 2019. Four years from committee discussion to enforceable regulation. It placed six substances on the list: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide. It formally excluded four others: oxitriptan, piracetam, silver protein mild and tranilast.

Those six are the only substances that have ever completed the journey. Twenty-nine years of statute, thirteen years of active nominations, one final rule.

The most underrated document in this story is a proposed rule from 2019

On 5 September 2019, six months after the first rule took effect, the FDA published a proposed rule for the second batch. It proposed adding five more substances and declining twenty-six.

It has never been finalised. The agency's own page on the 503A bulks list, content-dated 14 May 2026, still describes that rulemaking in the future tense: after considering public comments, it says, the agency will issue a final regulation.

Seven years, for five substances, none of them politically contested, none of them carrying a billion-dollar constituency, all of them already through committee. I think this is the single most informative fact available about how quickly the peptide question can actually move, and it is almost never cited, because it is boring and because it is not about peptides.

Coming out of Category 2 is not permission, and that gap is where the money is

Because the list itself moved so slowly, the FDA built a temporary structure beside it: an interim policy sorting nominated substances into three categories. Category 1 covers substances the agency does not intend to act against while it evaluates them. Category 2 covers substances where it has identified significant safety risks and would consider enforcement. Category 3 covers nominations too thin to evaluate at all.

In September 2023 the FDA placed BPC-157 in Category 2, alongside peptides including AOD-9604, CJC-1295 and ipamorelin acetate, citing immunogenicity, impurity profiles and the limited human data available. Compounding pharmacies stopped.

On 16 April 2026 the agency published a Federal Register notice announcing the advisory review and stating that the peptides under consideration would come out of Category 2 within seven calendar days. Twelve peptides in total: four for the 23 July session, three for 24 July, and five more, GHK-Cu, melanotan II, cathelicidin LL-37, dihexa acetate and PEG-MGF, scheduled for review before 28 February 2027.

This is where the public conversation went wrong, and it went wrong in a way that happens to benefit sellers. Coming out of Category 2 means the FDA has stopped saying it would consider enforcement on safety-risk grounds. It does not mean the substance is on the list. It does not mean it may lawfully be compounded. None of these twelve peptides was ever in Category 1, so there was no prior posture of tolerance to be restored, whatever the word "restored" has been doing in the marketing copy. The agency has separately said it will not assign categories at all to substances nominated on or after 7 January 2025, which quietly closes the side entrance behind everything nominated since.

What the July vote actually bought

Section 503A obliges the FDA to consult the advisory committee before issuing bulks list regulations. The consultation is a statutory prerequisite. It is not the decision, and it binds nobody.

On 23 and 24 July 2026 the committee recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, and declined emideltide. BPC-157, KPV and TB-500 each cleared 8 to 6 with one abstention. MOTS-c cleared 7 to 5 with two abstentions. The agency's own scientific reviewers had argued against.

What that produced is a procedural box with a tick in it. What still has to happen is a proposed rule, a public comment period, a reasoned response to those comments, and a final rule, with the Department of Health and Human Services engaged throughout. Every one of those steps is discretionary as to timing. Not one of them carries a statutory deadline.

The strongest case against my own reading

The counter-argument is serious and deserves to be stated properly rather than waved at. The 2019 batch was slow precisely because nobody cared. Five dermatology substances with no commercial constituency and no political sponsor will sit in a queue indefinitely, because nobody inside or outside the agency pays a cost for the delay. Peptides are the inverse. There is a Secretary of Health and Human Services personally committed to the outcome, a wellness economy measured in billions waiting on it, and a constituency that will generate noise every week the rule fails to appear. Agencies move quickly when the political cost of standing still exceeds the cost of acting.

That is true, and it is why I say unlikely rather than impossible. There are procedural accelerants available too, including interim final rules and direct final rules, which compress or bypass the ordinary comment sequence in limited circumstances.

Here is what the counter-argument does not solve. Speed raises litigation exposure. A rule that adds six substances over the written objection of the agency's own reviewers builds an administrative record that is unusually easy to attack as arbitrary and capricious under the Administrative Procedure Act. The faster the rule is drafted, the thinner that record is. Agency lawyers understand this better than anyone, and it is exactly the kind of consideration that adds months quietly, inside a building, with no announcement.

Where this leaves the actual legal position

As of today, 21 CFR 216.23 contains six substances. Not one is a peptide. No proposed rule adding any peptide has been published. Nothing that happened on 23 and 24 July changed the status of BPC-157, KPV, TB-500, MOTS-c, Epitalon or Semax under Section 503A by a single word.

I do not think most of the commerce currently running on these molecules is waiting for that to change. It is running on the impression that it already has. And the distance between a committee recommendation and a line in the Code of Federal Regulations is not a technicality separating two roughly equivalent things. It is the difference between an opinion and a law, and the record in this category suggests that distance is measured in years.

Watch the Federal Register, not the vote count. The day a proposed rule appears with a peptide named in it, the clock genuinely starts. Until that day, it has not started at all.

Ozemback, September 2026